Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them

1. A compound of formula I,

in which:

R1 is phenyl which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , methylsulfonyl, CF 3 , alkyl having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;

R2 is phenyl or naphthyl,

where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, COOMe, CONH 2 , alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , OH, methylsulfonyl, CF 3 , alkyl having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;

R3 is C p H 2p —R7;

p is 0, 1, 2, 3, 4or 5;

R7 is CH 3 , CH 2 F, CHF 2 , CF 3 , cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms, C≡CH, C≡C—CH 3 , alkoxy having 1, 2, 3 or 4 carbon atoms, or phenyl,

where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF 3 , OCF 3 , CN, COOMe, CONH 2 , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R4 is hydrogen or alkyl having 1, 2 or 3 carbon atoms;

R5 is hydrogen or alkyl having 1, 2 or 3 carbon atoms;

R6 is hydrogen, F, Cl, CF 3 or alkyl having 1, 2 or 3 carbon atoms;

X is CH;

or a pharmaceutically acceptable salt or trifluoroacetate thereof.

2. A compound of formula I as claimed in claim 1 , in which:

R1 is phenyl which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , methylsulfonyl, CF 3 , alkyl having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;

R2 is phenyl, 1-naphthyl, or 2-naphthyl,

where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, COOMe, CONH 2 , alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , OH, methylsulfonyl, CF 3 , alkyl having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;

R3 is C p H 2p -R7;

p is 0, 1, 2, 3, 4 or 5;

R7 is CH 3 , CH 2 F, CHF 2 , CF 3 , cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms, C≡CH, C≡C—CH 3 , alkoxy having 1, 2, 3 or 4 carbon atoms, or phenyl,

where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF 3 , OCF 3 , CN, COOMe, CONH 2 , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R4 is hydrogen or alkyl having 1, 2 or 3 carbon atoms;

R5 is hydrogen or alkyl having 1, 2 or 3 carbon atoms;

R6 is hydrogen, F, Cl, CF 3 or alkyl having 1, 2 or 3 carbon atoms;

X is CH;

or a pharmaceutically acceptable salt or trifluoroacetate thereof.

3. A compound of formula I as claimed in claim 1 , in which:

R1 is phenyl,

which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , methylsulfonyl, CF 3 , alkyl having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;

R2 is phenyl,

which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, COOMe, CONH 2 , alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , OH, methylsulfonyl, CF 3 , alkyl having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, acetyl, and methylsulfonylamino;

R3 is C p H 2p -R7;

p is 0, 1, 2, 3, 4 or 5;

R7 is CH 3 , CH 2 F, CHF 2 , CF 3 , cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms, C≡CH, C≡C—CH 3 , alkoxy having 1, 2, 3 or 4 carbon atoms, or phenyl,

where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF 3 , OCF 3 , CN, COOMe, CONH 2 , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R4 is hydrogen;

R5 is hydrogen;

R6 is hydrogen, F or alkyl having 1, 2, or 3 carbon atoms;

X is CH;

or a pharmaceutically acceptable salt or trifluoroacetate thereof.

4. A compound of formula I as claimed in claim 1 , in which:

R1 is phenyl,

which is unsubstituted or substituted by 1 substituent from the group consisting of F, Cl, Br, I, CN and alkoxy having 1 or 2 carbon atoms;

R2 is phenyl,

which is unsubstituted or substituted by 1 substituent from the group consisting of F, Cl, Br, I, CN and alkoxy having 1 or 2 carbon atoms;

R3 is C p H 2p -R7;

p is 0, 1, 2, 3;

R7 is CH 3 , cycloalkyl having 3 or 4 carbon atoms or phenyl,

where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, I, CN, alkyl having 1 or 2 carbon atoms and alkoxy having 1 or 2 carbon atoms;

R4 is hydrogen;

R5 is hydrogen;

R6 is hydrogen, F or alkyl having 1 or 2 carbon atoms;

X is CH;

or a pharmaceutically acceptable salt or trifluoroacetate thereof.

5. A compound of formula I as claimed in claim 1 , selected from:

1R′,2R′-1-(2-Cyclopropylmethoxy-1,2-diphenylethyl)-1H-pyridin-2-one,

1R′,2S′-1-[2-Cyclopropylmethoxy-1-(4-fluorophenyl)-2-(4-methoxyphenyl)ethyl]-1H-pyridin-2-one,

1-(2-Cyclopropylmethoxy-1,2-diphenylethyl)-5-fluoro-1H-pyridin-2-one,

1R′,2R′-5-Fluoro-1-(2-p-cyanophenoxy-1,2-di-p-fluorophenylethyl)-1H-pyridin-2-one,

1-[2-Cyclopropoxy-1,2-bis(4-fluorophenyl)ethyl]-5-fluoro-1H-pyridin-2-one,

1-[2-(4-Chlorophenyl)-2-cyclopropylmethoxy-1-phenylethyl]-1H-pyridin-2-one,

1R′,2R′-1-[2-Cyclopropylmethoxy-1,2-bis(4-fluorophenyl)ethyl]-1H-pyridin-2-one,

1R′,2S′-1-[2-Cyclopropylmethoxy-1,2-bis-(4-fluorophenyl)ethyl]-1H-pyridin-2-one,

1-[2-(4-Bromophenyl)-2-cyclopropylmethoxy-1-(4-fluorophenyl)ethyl]-1H-pyridin-2-one,

4-[1-Cyclopropylmethoxy-2-(4-fluorophenyl)-2-(2-oxo-2H-pyridin-1-yl)ethyl]benzonitrile,

1R′,2R′-1-(2-Cyclopropylmethoxy-1,2-diphenylethyl)-5-fluoro-1H-pyridin-2-one,

1R′,2R′-1-[1-(4-Fluorophenyl)-2-(4-methoxybenzyloxy)-2-(4-methoxyphenyl)ethyl]-1H-pyridin-2-one,

1-[2-Cyclopropylmethoxy-1,2-bis-(4-fluorophenyl)ethyl]-1H-pyridin-2-one,

4-[1-(4-Chlorophenyl)-2-(2-oxo-2H-pyridin-1-yl)-2-phenylethoxymethyl]benzonitrile,

1-[2-Cyclopropylmethoxy-1,2-bis-(4-fluorophenyl)ethyl]-5-fluoro-1H-pyridin-2-one,

1R′,2R′-1-[2-Cyclopropylmethoxy-1-(4-fluorophenyl)-2-(4-methoxyphenyl)ethyl]-1H-pyridin-2-one and

1R′,2S′-1-[1-(4-Fluorophenyl)-2-(4-methoxybenzyloxy)-2-(4-methoxyphenyl)ethyl]-1H-pyridin-2-one,

or a pharmaceutically acceptable salt or trifluoroacetate thereof.

6. A pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds as claimed in claim 1 as active ingredient, together with one or more pharmaceutically acceptable carriers or additives.